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Glutamate metabotropic receptors (mGluRs) in bovine brain coated vesicles have been characterized by pharmacological and kinetic binding 
experiments. Saturation experiments revealed a single binding site with a Kd = 607.9 f 78.5 nM and a B,,,,, = 6.45 f 0.88 pmol/mg protein. The 
specific binding of Lj3H]glutamate to mGluRs is regulated by guanine nucleotides. Guanosine-5’-triphosphate (GTP; 100 PM) shifts the agonist 
competition curves to the right, increasing the XC, values. Pertussis toxin treatment produces a pharmacological binding profile for quisqualate 
similar to that obtained in the presence of 1OOpM GTP. These results indicate the presence of metabotropic glutamate receptors in coated vesicles 
and its coupling to a pertussis toxin sensitive G-protein. 
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1. INTRODUCTION 
Glutamate (Glu), a major excitatory neurotransmit- 
ter, plays an important role in neuronal plasticity and 
neurotoxicity and is thought to be involved in many 
neuronal functions including memory acquisition, 
learning and some degenerative disorders such epilepsy 
and stroke [1,2]. The functional diversity of glutamate 
results from the presence of a wide variety of receptors, 
which can be categorized into two distinct groups, 
termed ionotropic and metabotropic (mGluR) [l]. Both 
kinds of receptors are functionally and pharmacologi- 
cally different. The ionotropioc glutamate receptors be- 
long to the superfamily of receptor channels, and have 
been termed according to their most selective agonists 
(NMDA, AMPA and kainic acid) [3,4]. The 
metabotropic glutamate receptors are coupled to G- 
proteins and evoke a wide variety of intracellular signal 
transduction pathways [5,6]. Recently, cDNA clones for 
five different subtypes of the mGluR have been de- 
scribed [7-91, suggesting the existence of a family of 
mGluRs which are expressed heterogeneously in the 
brain [8,10,11]. It is known that mGluR1 and mGluR5 
are linked to the PI hydrolysis/Ca2’ cascade [7,9,12] and 
mGluR2 is coupled to an inhibitory CAMP cascade 
[8,13,14]; nevertheless the precise signalling pathways of 
these receptors remain to be elucidated. On the other 
hand, the pharmacological characterization of mGluRs 
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is proving very difficult because of the lack of specific 
radioactive ligands. It is known that these receptors can 
be activated by quisqualic acid (QA), ibotenate (IBO) 
and more selectively by truns-(f)- 1 -aminocyclopentane 
1,3-dicarboxylic acid (t-ACPD) [15,16]. All these re- 
ports provide evidence of a novel family of seven trans- 
membrane G-protein-coupled receptors. 
Macromolecules are taken up into eukaryotic cells by 
endocytosis. One of the mechanisms for this process is 
mediated by cell surface receptors that cluster into 
clathrin-coated domains in the plasma membrane 
[17,18]. Receptors are collected in these regions either 
constitutively or after binding ligand and internalized 
by invagination and pinching off of clathrin-coated ves- 
icles [19]. Some reports have shown the presence in 
coated vesicles of receptors that are coupled to 
guanylnucleotide-binding proteins, like opioid recep- 
tors [20], /I-adrenergic receptors [21], muscarinic cholin- 
ergic receptors [22] and A,-adenosine receptors [23] in- 
dicating that these receptors might be internalized via 
a similar mechanism [24]. The precise pathway of recep- 
tor sequestration or internalization is unclear so far, but 
the presence of several G-protein coupled receptors in 
coated vesicles suggests that these organelles may be 
involved in receptor translocation and redistribution. In 
a previous report [25] we have described the presence of 
glutamate receptors (ionotropic and metabotropic) in 
bovine brain coated vesicles. In this article we have 
characterized them by kinetic and pharmacological 
binding experiments and the effect of GTP on the 
mGluR specific binding and its putative coupling to a 
pertussis toxin-sensitive G-protein has been studied. 
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2. MATERIALS AND METHODS 
2.1. Materials 
t$H]Glutamic acid (54.7 Wmmol) was obtained from Dupont- 
NEN (Boston, MA, USA). Pertussis toxin was from List Biological 
Laboratories. Guanosine triphosphate was purchased from Boehrin- 
ger Mannheim. L-Glutamic acid, IBO, QA and other reactives were 
from Sigma (St. Louis, MO, USA). t-ACPD was from Tocris Neu- 
ramin (Essex, UK). The Sephacryl S-1000 gel filtration column and 
Ficoll400 were from Pharmacia (Sweden). All other reagents were of 
analytical grade. 
2.2. Preparation of bovine bram membranes and coated vesicles 
All steps were carried out at 4°C. Bovine brains were obtained at 
a local abattoir. For membrane preparation, 2 g of cerebral cortex 
were minced and homogenized in a buffer containing a mixture of 
protease inhibitors (100 PM PMFS, 7.3 mu/ml bacitracin), and a P, 
fraction was prepared as described by Recasens et al. [26], using 10 
mM phosphate buffer, pH 7.5 [25]. Coated vesicles were purified from 
bovine cerebral cortex by Sephacryl S-1000 gel filtration according to 
a modification of several published procedures [23,27,28]. 
2.3. Radioligand binding assays 
Metabotropic glutamate receptors were determined using L- 
[‘HIglutamate as radioligand. Binding assays were performed as previ- 
ously reported [25,29,30]. Unless otherwise indicated, 70-100 pg of 
Triton-treated coated vesicles or other membrane fractions were incu- 
bated for 60 min at 22°C in the presence of 40 nM L-[‘HIglutamate, 
100 PM AMPA, 100 PM NMDA and 100 PM KA in 10 mM potas- 
sium phosphate buffer, pH 7.4, to define total binding. Non-specific 
binding (cpm obtained in the presence of 100pM of the specific ligand: 
QA, IBO, t-ACPD) was substracted from total binding to obtain 
specific binding. For competition experiments, different concentra- 
tions of the indicated specific agonists were used under the above 
conditions. Saturation analysis was performed using different concen- 
trations of L-[‘HIglutamate (10 nM to 1,500 nM) in the presence of 100 
PM AMPA, 100 PM NMDA and 100pM KA (total binding), and in 
the presence of unlabeled glutamate at a concentration of 10’ of the 
radioligand to obtain nonspecific binding K,, and B,,,,, were deter- 
mined by Scatchard analysis. All these experiments were performed 
in the absence and in the presence of 100 PM GTP. 
2.4. Pertussis toxin ADP-ribosylation 
Pertussis toxin ADP-ribosylation was carried out as described ear- 
lier [31]. Coated vesicles were incubated with preactivated pertussis 
toxin (1 pg PT/lOOpg protein) or vehicle for 30 min at 3O’C in a final 
volume of 1 ml of 100 mM potassium phosphate buffer, pH 7.4. After 
incubation, samples were centrifuged at 100,000 x g for 30 min and 
treated with Triton X-100 and used for binding experiments. In all 
these experiments, coated vesicles were rechromatographed through 
the Sephacryl S-1000 column to assure the purity of the preparation. 
2.5. Protein determination 
Protein concentration was determined by the method of Lowry et 
al. [32] using bovine serum albumin as standard. 
2.6. Sodium dodecyl surfate polyacrylamide-gel electrophoresis 
Samples containing 50 pg protein were analyzed on polyacrylamide 
gradients gels (7.5515%) containing 0.1 sodium dodecyl sulfate (SDS) 
]331. 
3. RESULTS AND DISCUSSION 
Bovine brain coated vesicles were obtained as de- 
scribed previously [23] after one or two passages on a 
Sephacryl S-1000 column to ensure purity. This method 
yields a coated vesicle preparation with minimal con- 
tamination with other subcellular fractions. Purity was 
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Fig. 1. SDS-PAGE of a coated vesicle preparation. Samples (50 fig of 
protein) of different fractions were loaded in a SDS-PAGE. Lane 1, 
sample before S-1000 column; lane 2, peak I; lane 3, coated vesicles 
(peak II); lane 4, rechromatographed coated vesicles; lane 5, bovine 
brain membranes. 
assessed by several enzyme markers as described earlier 
[22,23]. Analysis by SDS-PAGE (Fig. 1) confirmed that 
peak II (lanes 3 and 4) contain mostly coated vesicles 
showing the clathrin heavy chain (M, = 180,000) as the 
major component [34] as well as the light chains (M, = 
30,000-36,000) and the other two major family proteins 
(100,000-l 15,000; 50,000-55,000) implicated in clathrin 
assembly to the plasma membranes, termed adaptor 
proteins [35]. Lanes 1 and 2 correspond to the proteins 
of sample before S-1000 column and peak I, respec- 
tively. Peak I showed a small quantity of 180,000 
clathrin heavy chain. Crude synaptic membranes (lane 
5) as well as the former samples present a different 
electrophoretic pattern profile than coated vesicles. This 
agrees with our previous reports [23,25] and with other 
authors [17,28] who also found the same electrophoretic 
profiles, and besides they conclude that most of the 
bovine brain coated vesicles derive from neuronal cells 
and are implicated in the vesicular neuronal membrane 
traffic pathways [28]. To assess the presence of 
metabotropic glutamate receptors in bovine brain 
coated vesicles, L-[3H]glutamate was used as radioli- 
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Table I 
Specific binding of L-[3H]glutamate o metabotropic glutamate recep- 
tors in various subcellular fractions 
Fractions Specific binding 
(pmol/mg protein) 
Bovine brain membranes 0.121 + 0.031 (7) 
Before S-l ,000 column 0.215 f 0.016 (3) 
Peak I 0.443 f 0.032 (4) 
Peak II 0.666 f 0.050 (6) 
Different fractions were treated with 0.04% Triton X-100 and incu- 
bated in the presence of 40 nM [>H]glutamate, 100 PM NMDA, 100 
PM AMPA and 1OOpM KA (total binding). Non-specific binding was 
determined in the presence of 100 ,uM t-ACPD. Data are means 
(fS.E.M.) of the experiments indicated in parentheses, performed in 
triplicate each using different preparations. 
gand. Metabotropic glutamate receptors were measured 
in bovine brain membranes and different fractions ob- 
tained during coated vesicles purification. As it can be 
seen in Table I specific binding in peak II (coated vesi- 
cles) to mGluR using t-ACPD as specific agonist repre- 
sents 550% of the binding found in the bovine brain 
membranes and 150% of the binding found in peak I. 
Taken into the account that the cross-contamination 
between peaks I and II was minimal [22,23] and that the 
electrophoretic pattern (Fig. 1) of bovine brain mem- 
branes and coated vesicles were clearly different, these 
results support the evidence of the presence of 
metabotropic glutamate receptors in bovine brain 
coated vesicles. Furthermore these data confirm our 
previous results where, under these conditions, the 
mGluRs found in bovine brain coated vesicles repre- 
sented 45-50% of the total Lj3H]glutamate binding sites 
~251. 
To further characterize the mGluRs present in bovine 
brain coated vesicles and considering that these recep- 
tors are coupled to G-proteins [5,6], the kinetic and 
pharmacological characteristics in the absence and in 
the presence of GTP were studied. Fig. 2 shows the 
saturation binding experiments in the absence of gua- 
nine nucleotide. Scatchard plot (inset) indicates the 
presence of one binding site with a Kd value of 607.9 k 
78.5 nM and a B,, of 6.45 & 0.88 pmol/mg protein. The 
Kd value is similar to the Kd reported earlier [25] for 
t_-[3H]glutamate binding sites and B,,, represents 55% 
of the total glutamate receptors (ionotropic and 
metabotropic) found in coated vesicles [25]. When these 
studies were performed in the presence of 100 PM GTP 
(Table II) kinetics parameters (Kd and B,,,,,) were in- 
creased. It is well known that receptors whose action is 
mediated through a G-protein show a lower affinity for 
its agonists in the presence of GTP. GTP produces a 
transition of the receptors from the high- to the low- 
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Fig. 2. Saturation binding curve for glutamate metabotropic receptors in bovine brain coated vesicles. Binding assays were performed as described 
in section 2. The data points are means (+S.E.M.) of four individual experiments made in triplicate, each using different coated vesicles preparation. 
Inset shows Scatchard plot analysis from the data of saturation curve giving a Kd = 607.9 + 78.5 nM and a B,,,,, = 6.45 f 0.88 pmohmg prot. At 
either radioligand concentration -5&55% of total L-[‘HIglutamate binding was specific. Total binding was between 0.6% and 1.2% of the total 
amount of radioactivity in the assay (maximum 300,000 cpm). 
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Volume 316, number 2 FEBS LETTERS January 1993 
Table II Table III 
Saturation data for the L-[3H]glutamate binding to mG1uRs Effect of GTP on the specific binding of metabotropic glutamate 
receptors in bovine brain coated vesicles 
-GTP +GTP 
& (nM) 607.9 f 78.5 1,440 + 30 
k,, (pmoumg prot.) 6.45 f 0.88 9.35 f 1.5 
Binding assays were performed as described in section 2. Data are 
Specific binding (pmol/mg protein) 
obtained as described in the legend to Fig. 2. 
affinity state [36]. In our conditions, it is possible that 
in the absence of GTP we only detect the binding sites 
corresponding to the low-affinity state; however, an in- 
crease in the B,,,,, and K,, values are observed in the 
presence of GTP suggesting that a transition from the 
high- or middle- to the low-affinity state could take 
place in the presence of guanine nucleotides [37]. In 
agreement with these data, it has been reported that 
receptors in several agonists affinity states may be pres- 
ent depending on lipid environment [38]. The lack of 
specific radioligands make a better kinetic characteriza- 
tion of the mGluRs difficult. 
-GTP +GTP 
Glutamate 0.726 k 0.043 (100%) 0.575 + 0.012 (79%) 
Quisqualate 0.630 + 0.058 (100%) 0.274 f 0.077 (43%) 
Ibotenate 0.585 r 0.066 (100%) 0.258 + 0.02 (44%) 
t-ACPD 0.713 f 0.022 (100%) 0.307 f 0.03 (43%) 
Triton-treated coated vesicles were incubated for 60 min at 22°C in 
the presence of 40 nM L-[‘HIglutamate, 100 PM NMDA, 100 PM 
AMPA and 100 PM KA in phosphate potassium buffer (total bind- 
ing), in the absence or in the presence of 100 PM GTP. Non-specific 
binding was determined in the presence of 100 PM of the indicated 
agonists. Data are means (+S.E.M.) of four separated experiments 
performed in triplicate. 
When bovine brain coated vesicles were incubated in 
the absence or in the presence of 100 PM GTP and 
non-specific binding to mGluRs was obtained in the 
presence of 100pM of the indicated agonists (Table III), 
specific binding was reduced by more than 50% in all 
cases except for L-glutamate. These results were con- 
firmed with the competition binding experiments using 
different concentrations of specific agonists (t-ACPD, 
QA, IBO) (Fig. 3). The pharmacological profiles in the 
absence of GTP show that t-ACPD is the most specific 
agonist. These results agree with the pharmacological 
response of mGluR2 on the inhibition of CAMP forma- 
tion [8], as well as with other reports which show that 
t-ACPD is a more potent agonist than QA and IBO in 
stimulating PI metabolism in different brain regions 
[6,15]. Moreover, when these experiments were per- 
formed in the presence of 100 ,uM GTP, the dose-re- 
sponse curves shifted to the right, increasing the I& 
values (Fig. 3). All these results confirm the coupling of 
the mGluRs found in bovine brain coated vesicles, to 
a G-protein. 
As has been pointed out above, the existence of sev- 
eral forms of metabotropic glutamate receptors by 
pharmacological [ 13,161, electrophysiological [5,39] and 
cloning approaches [7-91 has been shown. Furthermore, 
it is well known that some of the effects of these recep- 
tors are pertussis toxin-sensitive [9,12,14,40] and some 
others are not [9,41,42], depending on the cell type stud- 
ied. The effect of PTX on mGluR binding was investi- 
gated by treatment of bovine brain coated vesicles with 
,, I. 
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Fig. 3. Effect of GTP on agonists competition curves in bovine brain coated vesicles. Specific binding of L-[‘HIglutamate to mGluRs in the absence 
(0) or in the presence (0) of 100 PM GTP was determined at various concentrations of the indicated specific agonists. Results are expressed as 
percentage of maxima1 specific binding in each case. Binding was performed as described in section 2. The data points are obtained as described 
in the legend of Fig. 2. IC,, values are means (fS.E.M.) of four individual experiments made in triplicate. Maximal specific binding in each case 
is expressed in Table III. 
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Fig. 4. Pertussis toxin effect on quisqualic acid competition curves in 
bovine brain coated vesicles. Specific binding of L-[‘HIglutamate to 
mGluRs in untreated (e,n) and treated (0) pertussis-toxin coated 
vesicles was determined in the absence (o,o) and in the presence of 100 
PM GTP (0) at indicated concentrations of QA. Results are expressed 
as percentage of maximal specific binding in each case. Data points 
are obtained as described in the legend of Fig. 2. IC,, values are means 
(+S.E.M.) of four individual experiments made in triplicate. Maximal 
specific binding was (0) 0.712 + 0.039 pmoVmg protein; (0) 0.363 f
0.047 pmol/mg protein; (0) 0.346 f 0.012 pmoVmg protein. 
1 ,ug PTX/lOO ,ug protein, prior to the QA competition 
binding experiments. Fig. 4 shows that PTX treatment 
produces the same effect as guanine nucleotides. The 
PTX competition curve shifts to the right, causing an 
appreciable increase of the IC,, value. Supporting these 
data, we have previously reported the presence of per- 
tussis toxin substrates in bovine brain coated vesicles 
[431. 
These results show that metabotropic glutamate re- 
ceptors present in bovine brain coated vesicles are cou- 
pled to a pertussis toxin-sensitive G-protein. This, and 
the fact that a wide number of G-protein coupled recep- 
tors are present in coated vesicles [20-231 as well as 
other proteins implicated in signal transduction sys- 
tems, such as adenylate cyclase [21,23], G-proteins [43] 
and phospholipase C [31], which suggests that these 
organelles may play a role in the translocation and/or 
the regulation of G-protein-coupled receptors [24,44]. 
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